A little irritated are we, Mr Happynut. Thought you said you liked me. Let me tell you a secret. I wouldn't be here if I had't made money on this stock. Till later, Chuckles.
It would have been much worse had it not been for the shorts covering today. Yesterdays short trades were only 21% of total trades. Shorts are controlling this stock.
No, I'm not a paid short. I'm not crazy about Zack either but found this a good summary with a twist, and wanted comments from the board. Currently I own 14,195 shares. Hardly a short.
Although the study met its formal endpoints, the company’s shares declined. The company has no plans to move the
program into phase III.
The company has very few
candidates in its pipeline,
most of which are yet to
enter the late stage of
from the studies may affect
Positive on Collaboration Agreements: Agenus has collaboration agreements with a number of companies, which not only provide
it with funds in the form of upfront and milestone payments and future royalties, but also validate the company’s proprietary
product platform. The global hematology-oncology alliance between Agenus and Incyte focuses on four immune checkpoint
targets, GITR, OX40, TIM-3, and LAG-3. Per the terms of the agreement, Agenus and Incyte will share all costs and profits for the
GITR and OX40 antibody programs equally, with Agenus eligible for milestones. Both TIM-3 and LAG-3 are royalty bearing
programs that will be funded by Incyte entirely, while Agenus will be eligible for milestones and royalties. Agenus received a $60
million upfront payment and is eligible to receive up to $350 million in development, regulatory, and commercial milestones for the
four lead programs.
Below is a par of Zack analysis:
Pipeline Yet to Deliver: Agenus has only a few candidates in mid-stage of development
including Prophage Series vaccine and a number of QS-21 Stimulon-containing vaccine
candidates. Some drugs like Roche’s Avastin and Eisai/Arbor’s Gliadel Wafer are
already approved for GBM. Meanwhile, several companies including Pfizer,
AstraZeneca, Curetech and Tesaro are developing antibody-based candidates directed
to the same target as some of Agenus’ programs.
Dependence on Partners: Agenus is highly dependent on its collaboration partners for
the development of its candidates. Prophage Series vaccine is in a phase II study
(surgically resectable recurrent glioma) sponsored by the Alliance for Clinical Trials in
Oncology, a cooperative group of the National Cancer Institute. The company entirely depends on the sponsor for the study design,
timelines and data availability. If any of its partners fail to receive regulatory approvals or terminate a deal, Agenus’ future prospects
would be hampered. For example, in Apr 2014, Glaxo announced the termination of a phase III study on its MAGE-A3 cancer
immunotherapeutic vaccine (containing QS-21 Stimulon) in non-small cell lung cancer. Earlier, in 2013, Glaxo’s phase III study on
the vaccine for melanoma had failed to meet its first co-primary endpoint. However, the study is being continued until completion of
its second co-primary endpoint.
Development Setbacks: For a development-stage company like Agenus, investor focus remains on the status of pipeline candidates.
Any unfavorable outcome from ongoing studies may affect shares to a large extent. In Jun 2014, Agenus reported that a phase II
study on its HerpV vaccine candidate for genital herpes could not clearly determine whether the magnitude of the effect on viral load
would be sufficient to significantly reduce the incidence, severity or duration of herpetic lesions or reduce the risk of viral
transmission. Although the study met its formal endpoin